Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 2,462 matching trials from the live ClinicalTrials.gov search.
Conditions
Klinefelter Syndrome, Trisomy X, XYY Syndrome, XXXY and XXXXY Syndrome, Xxyy Syndrome, Xyyy Syndrome, Xxxx Syndrome, Xxxxx Syndrome, Xxxyy Syndrome, Xxyyy Syndrome, Xyyyy Syndrome, Male With Sex Chromosome Mosaicism
Interventions
Assessments of Development and Growth
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Weeks to 13 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Autism Biomarker Consortium for Clinical Trials (ABC-CT): Follow-up Study

NCT04841525
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
6 Years to 11 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Epilepsy in Children, Epilepsy
Interventions
Attention Intervention using a customized BCI decoder, Attention Intervention without using a customized BCI decoder
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Show Me to Help Me

NCT01311596
Conditions
Autism
Interventions
Icons
Other
Lead sponsor
Akron Children's Hospital
Other
Eligibility
4 Years to 18 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Conditions
Congenital Heart Disease in Children, Hypoxia, Neurodevelopmental Disorders, Complex Congenital Heart Disease
Interventions
Single Arm, Neonatal Neurobehavioral Scale
Procedure
Lead sponsor
University of Utah
Other
Eligibility
0 Years to 52 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Scarborough, Maine + 1 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Methylphenidate and Response to Alcohol Cues Pilot Study

NCT06063200
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 25 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood
Interventions
Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Conditions
ADHD, Cannabis Use Disorder
Interventions
Delayed-release, extended-release methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 26 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Drug · Other
Lead sponsor
Corium, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Healing Minds Biofeedback and Breathing Practices Intervention
Behavioral
Lead sponsor
Hoskinson Health and Wellness Clinic
Industry
Eligibility
6 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gillette, Wyoming
Conditions
Autism Spectrum Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions
Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Autism
Interventions
Trichuris Suis Ova
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Air Pollution and Development in the Boricua Youth Study

NCT05368493
Conditions
Pollution; Exposure, Neurodevelopmental Disorders
Interventions
MRI task
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Months to 11 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

Virtual Reality Attention Management

NCT03221244
Conditions
ADHD
Interventions
VR Treatment, VR Active Control
Device
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Sacramento, California
Conditions
Intellectual Disability, Mild to Moderate, Developmental Disability
Interventions
Ready to Ride - Standard Delivery, Ready to Ride - Peer Support Delivery
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 27 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Durham, New Hampshire
Conditions
Autism
Interventions
Procedure alteration and occupational therapy
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
5 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 2 Interventional Results available

hCT-MSC in Children With Autism Spectrum Disorder

NCT04089579
Conditions
Autism, Autism Spectrum Disorder
Interventions
Cord Tissue Mesenchymal Stromal Cells, Placebo Infusion
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
4 Years to 11 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Attention Deficit Hyperactivity Disorder, Dyslexia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Mixed salts of a single-entity amphetamine, Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia